{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:06:04Z","timestamp":1759017964990,"version":"3.44.0"},"reference-count":4,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.annder.2018.10.016","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T01:40:41Z","timestamp":1541727641000},"page":"802-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Maladie de Grover sous anti PD-1\u00a0pour m\u00e9lanome m\u00e9tastatique"],"prefix":"10.1016","volume":"145","author":[{"given":"M.","family":"Amini-Adle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Balme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2018.10.016_bib0025","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2018.10.016_bib0030","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/bjd.13058","article-title":"First report of ipilimumab-induced Grover disease","volume":"171","author":"Munoz","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2018.10.016_bib0035","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cup.13312","article-title":"Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: a spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions","volume":"45","author":"Chen","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2018.10.016_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40425-016-0157-6","article-title":"A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4\u00a0but not PD-1","volume":"4","author":"Uemura","year":"2016","journal-title":"J Immunother Cancer"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196381831189X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196381831189X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:06:27Z","timestamp":1758971187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S015196381831189X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":4,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S015196381831189X"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2018.10.016","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maladie de Grover sous anti PD-1\u00a0pour m\u00e9lanome m\u00e9tastatique","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2018.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}